Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
about
Everolimus in the Treatment of Metastatic Breast CancerPhosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer3-Dimensional culture systems for anti-cancer compound profiling and high-throughput screening reveal increases in EGFR inhibitor-mediated cytotoxicity compared to monolayer culture systemsPhase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancerTAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancerThe mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cellsComparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.Identification of mTORC2 as a necessary component of HRG/ErbB2-dependent cellular transformationPhase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivityCombined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.Treating breast cancer in the 21st century: emerging biological therapiesCurrent status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistancePersonalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.The effect of Helicobacter pylori CagA on the HER-2 copy number and expression in gastric cancer.Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia.Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer.The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.High-throughput measurements of the optical redox ratio using a commercial microplate reader.Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1Assessment of tumor response to tyrosine kinase inhibitorsRapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report.Metformin: multi-faceted protection against cancer.Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directionsp130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatmentA phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancerRole of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancerOptical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer.
P2860
Q26784920-592C8A23-EBB4-4668-A137-1A46C638A8AFQ26862550-AAC84669-5FE6-4636-9C60-B8891DB827A4Q28543168-69E56D14-F8B8-4630-ABC6-724FF4D4DCD9Q33414349-8017B4B1-2FF9-4782-8889-FC8C4900BB7CQ33442621-F8F15EBB-06DA-41FA-8D06-9DB1DD87B4A6Q33591690-B39AB85E-19BC-4106-B95E-26D6DD4228DAQ33670472-A8653AF0-CFBF-4866-9C76-6E808EB16494Q33674656-0DEBEAC0-1980-4264-A1D5-B326195B6BFAQ33758255-8032A497-A98D-44BF-BBCA-826D01F95390Q33810494-896F8362-F74D-4971-BFAB-D80C9F43E569Q34036041-7BDA842D-47B2-485C-AE1F-D7DDF11E49C0Q34135475-89A98832-CBA6-4E8C-AA2C-F99BCAF22389Q34147910-03299B58-06DD-4DCF-8524-37C4FA3920D6Q34205196-A793CEC9-6BCE-47B8-9379-36C3014F8AE4Q34326536-47EAC7B9-9195-4803-A308-F2D83F63A537Q34355748-746C045E-8043-4590-88CE-3AB31D48CFE6Q34664129-C0ED6667-3A00-4CC2-BACC-D5EE37E26BBAQ34855628-3735AABB-BD79-4C34-AC5F-FD79FBE1B388Q34926036-7318143C-85B0-4B9A-8561-E0447D8C1D40Q34979662-B13FD8F4-7B49-4072-BB4F-39B0542FEA87Q34995919-DD7DF6DE-F77B-4015-9E08-B8C2265A59BFQ35018233-3E8ADECE-2A8E-4160-9743-2477FDDCA527Q35029198-684E4B11-3ADE-4F65-AC44-5921765E6729Q35031049-1D5B5BDC-1E2F-44B1-8F76-D6747A08BB1EQ35218681-AE20AA41-0431-4C65-8210-A39A0C0C078DQ35558589-2EA12740-0EDD-4357-88E0-FBEFB1D274BCQ35584253-D5C30D19-3BAC-4600-B622-7884A6A0DEC0Q35764409-99B69CB5-890E-44CA-90E8-06D05953F41FQ35783451-ED3F612A-43D1-4A98-A8FB-85A3CC7990FEQ35849919-E735BF78-03D3-457A-AA03-574568B6385FQ35861503-3202F3DE-2541-47D7-83B9-E3CC8A09D1B4Q36321147-69D8DC94-4AE9-43B7-A7F8-47B11F66DEE4Q36408570-4CE60D32-E570-4196-B603-FE16FE500A7AQ36629854-30D79E8C-0150-4AAC-A9DC-8C640BD2A014Q36782465-594C42FB-7DAE-46FF-9BDB-186AE7F1FB31Q36863266-5D94E640-6AC4-4198-80E9-51E91F9EFE6AQ36997524-E25AD57A-A6BE-429E-9E52-5363DAD6C36DQ37107395-0C2714A5-7335-4F52-B7FB-FB8059CB7FC2Q37174362-EB4F4C58-3E48-4F14-936E-8878DA2EF119Q37241740-EEF1C3F7-AED2-46E3-AB43-4B869C50AE36
P2860
Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Inhibition of mammalian target ...... 2-overexpressing cancer cells.
@en
Inhibition of mammalian target ...... 2-overexpressing cancer cells.
@nl
type
label
Inhibition of mammalian target ...... 2-overexpressing cancer cells.
@en
Inhibition of mammalian target ...... 2-overexpressing cancer cells.
@nl
prefLabel
Inhibition of mammalian target ...... 2-overexpressing cancer cells.
@en
Inhibition of mammalian target ...... 2-overexpressing cancer cells.
@nl
P2093
P2860
P1476
Inhibition of mammalian target ...... 2-overexpressing cancer cells.
@en
P2093
Archana Narasanna
Carlos L Arteaga
Chirayu Shah
H Charles Manning
J Phillip Kennedy
James T Forbes
Maria G Olivares
Nara de Matos Granja
Rebecca S Cook
Shelby K Wyatt
P2860
P304
P356
10.1158/1078-0432.CCR-09-1665
P407
P577
2009-11-24T00:00:00Z